IBRX enters its June 9 earnings release with a lending market that has rarely been looser than "very tight." Availability has dropped to just 6.2% — meaning fewer than seven shares remain available to borrow for every hundred already lent out. That number has been squeezing lower all week, down about 13% over the past seven days. Short interest itself is a substantial 13.5% of free float on ORTEX's daily estimate, though FINRA's fortnightly data (settled May 15) pegs the position even higher, with days-to-cover running at 10.6 — making it genuinely difficult for short sellers to unwind quickly. Cost to borrow has climbed back to 4.2%, up roughly 16% on the week, reversing a month-long decline from early-May highs above 6%. The stock shed 8% over the past month to $6.92, including a 5% drop on Friday alone. Options positioning, by contrast, is remarkably calm: the put/call ratio at 0.31 is right on its 20-day average with a near-zero z-score, nowhere near either extreme of its 52-week range.
The bull case rests on a pipeline that is rapidly broadening beyond ANKTIVA's approved BCG-unresponsive bladder cancer indication. ImmunityBio presented data across lung and bladder cancer at ASCO 2026 last week, and its JNJ collaboration on TAR-200 represents institutional validation of the platform's depth. The two analysts covering the stock both maintain Buy ratings — HC Wainwright reiterated with a $15 target on June 2 — and consensus price targets span $12–$23 against a $6.92 stock price, implying substantial implied upside across the coverage. The bear case is harder to dismiss, however. A PDUFA decision for a new ANKTIVA indication is not until January 2027, leaving the commercial franchise dependent on current bladder cancer uptake. Bears flag potential advisory committee headwinds, reimbursement friction, and concentration risk in the US market. The company's ORTEX short score has been climbing steadily, reaching 79.1 on June 4 — ranking in the bottom 4th percentile for short-side pressure across the universe.
One feature of IBRX's ownership structure stands out: founder and Chief Medical Officer Patrick Soon-Shiong, along with affiliated entities California Capital Equity and NantWorks, collectively controls around 62% of shares outstanding. That concentration compresses the true free float considerably, amplifying the effect of the elevated short position on per-share availability — which helps explain why borrow has tightened so sharply even as the absolute share count of shorts is only marginally higher week-on-week. The factor score backdrop reflects a company with striking EPS momentum (99th percentile over 30 days, 94th over 90 days) and high earnings surprise history (98th percentile), even as quality and value metrics remain weak — consistent with a pre-profitability commercial-stage biotech leaning heavily on a single approved asset.
Recent earnings reactions have been asymmetric and event-specific: a March 3 print produced a 14% single-day drop followed by a 23% five-day slide, while a May 8 event generated a 4.5% one-day gain. The June 9 print tests whether progress on commercial ANKTIVA uptake and pipeline data, including the ASCO lung cancer readout, can shift the narrative toward a broader platform story — or whether execution concerns and the long wait for the next approval keep the bears firmly in control.
See the live data behind this article on ORTEX.
Open IBRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
